Development of a microfluid device for the quantification of extracellular vesicles secreted in prostate cancer and for analysis of their RNA content (PROCEX) (Q3056500)
Jump to navigation
Jump to search
Project Q3056500 in Latvia
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of a microfluid device for the quantification of extracellular vesicles secreted in prostate cancer and for analysis of their RNA content (PROCEX) |
Project Q3056500 in Latvia |
Statements
444,810.81 Euro
0 references
540,540.54 Euro
0 references
82.29 percent
0 references
1 May 2021
0 references
30 November 2023
0 references
Atvasināta publiska persona "Latvijas Biomedicīnas pētījumu un studiju centrs"
0 references
56°54'57.24"N, 24°9'56.95"E
0 references
56°58'59.81"N, 24°1'53.44"E
0 references
Šī projekta mērķis ir izstrādāt principiāli jaunu tehnoloģiju ne-invazīvai prostatas vēža (PC) diagnostikai un monitoringam, balstoties uz PV specifisko ekstracelulāro vezikulu (EV) kvantificēšanu un to RNS satura analīzi. Šajā tehnoloģijā būs apvienota vairāku soļu mikrofluīdikas sistēma ar optiskiem rezonatoriem un jauni reaģenti – nanovielas, kas dod iespēju izolēt PV producētās EVs subpopulācijas no cilvēka bioloģiskajiem šķidrumiem, un analizēt to RNS saturu. Galvenais šī projekta iznākums būs PROCEX ierīces prototips. Projekta noslēgumā, ierīce tiks testēta ar labi anotētas PV pacientu kohortas un kontroles grupas asins un urīna paraugiem. Mēs sagaidām, ka šajā projektā izstrādātā ierīce dos iespēju uzlabot prostatas vēža diagnostiku un ārstēšanas efektivitāti, veicot vienkāršu, ātru un lētu asins vai urīna analīzi. Pašlaik šī tehnoloģija ir TRL2 līmenī un mēs sagaidām, ka projekta beigās tā sasniegs TRL4.Šis projekts atbilst RIS3 virzienam “Nākotnes izaugsmes tautsaimniecības nozares, kurās eksistē vai var rasties produkti un pakalpojumi ar augstu pievienoto vērtību” divās specializācijas jomās: “biomedicīna, medicīnas tehnoloģija, biofarmācija un biotehnoloģija” un “viedie materiāli, tehnoloģijas un inženiersistēmas”, un atbilst NACE 72.11. Projekta sagaidāmie rezultāti dos ieguldījumu veselības aprūpes nozares attīstībā (NACE 86). Šis projekts atbilst rūpniecisko pētījumu kategorijai un nav saistīts ar saimniecisko darbību.Šis ir starpdisciplinārs pētījums, kurā, atbilstoši OECD klasifikācijai, iesaistītas bioloģijas (1.6.), fizikas (1.3), datorzinātnes un informātikas (1.2.), bāzes medicīnas (3.1.), materiālu inženierijas (2.5) un medicīniskās inženierijas (2.6), kā arī nanotehnoloģijas (2.10) zinātņu nozares.Šis projekts tiks īstenots sadarbībā starp Latvijas Biomedicīnas pētījumu un pētījumu centru (BMC) un SIA Cellboxlab – Cietvielu Fizikas institūta (CFI) darbinieku izveidoto jaunuzņēmumu. Projekta īstenošanā tiks iesaisti divi jaunie zinātnieki (>25% no kopējās noslodzes), kā arī studenti un doktora grāda pretendenti (>25% no kopējās noslodzes). Projekts tiks īstenots, sākot ar 2021. gada 1. maiju un tā ilgums ir 31 mēnesis (30 mēneši no vienošanās noslēgšanas). Projekta darbību īstenošana tiks uzsākta pirms vienošanās par projekta īstenošanu parakstīšanas. Projekta kopējais attiecināmais finansējums ir 540 540.54 EUR, no kā ERAF finansējums sastāda 444 810.81 EUR.Atslēgas vārdi: ekstracelulārās vezikulas, prostatas vēzis, mikrofluīdika, šķidrās biopsijas, optiskie biosensori. (Latvian)
0 references
The aim of this project is to develop a fundamentally new technology for the diagnosis and monitoring of non-invasive prostate cancer (PC) based on PV-specific extracellular vesicles (EV) quantification and analysis of their RNA content. This technology will combine a multi-step microfluidic system with optical resonators and new reagents – nano-substances – which allow to isolate EVs subpopulations produced by PV from human biological fluids and to analyse their RNA content. The main outcome of this project will be the prototype PROCEX device. At the end of the project, the device will be tested with well annotated PV patients cohort and control group blood and urine samples. We expect that the device developed by this project will make it possible to improve the diagnosis of prostate cancer and the effectiveness of treatment by carrying out simple, fast and inexpensive blood or urine analysis. Currently, this technology is at the level of TRL2 and we expect that at the end of the project it will reach TRL4.This project follows the direction of RIS3 “Future growth economic sectors where high added value products and services exist or may be developed” in two areas of specialisation: “biomedicine, medical technology, biopharmaceuticals and biotechnology” and “smart materials, technologies and engineering systems” and corresponding to NACE 72.11. The expected results of the project will contribute to the development of the health sector (NACE 86). This project corresponds to the category of industrial research and is not related to economic activities.This is an interdisciplinary study that, according to OECD classification, involves branches of biology (1.6), physics (1.3), computer science and informatics (1.2), basic medicine (3.1), material engineering (2.5) and medical engineering (2.6), as well as nanotechnology (2.10) sciences (2.10) sciences.This project will be implemented in cooperation between the Latvian Biomedical Research and Research Centre (BMC) and medical engineering (2.6), as well as nanotechnology (2.10) sciences.This project will be implemented in cooperation between the Latvian Biomedical Research and Research Centre (BMC) and medical engineering (2.6), as well as nanotechnology (2.10) sciences.This project will be implemented in cooperation between the Latvian Biomedical Research and Research Centre (BMC) and medical engineering (2.6), as well as nanotechnology (2.10) sciences.This project will be implemented in cooperation between the Latvian Biomedical Research and Research Centre (BMC) and medical engineering (2.6), as well as nanotechnology (2.10) sciences.This project will be implemented in cooperation between the Latvian Biomedical Research and Research Centre (BMC) and medical engineering (2.6), as well as nanotechnology (2.10) sciences (2.10) in cooperation between the Latvian Biomedical Research and Research Centre (BMC) and medical engineering (2.6), as well as nanotechnology (2.10) sciences (2.10) in cooperation between the Latvian Biomedical Research and Research Centre (BMC) and medical engineering (2.6), as well as nanotechnology (2.10) sciences (2.10) in collaboration between the Latvian Biomedical Research and Research Centre (B Two young scientists (> 25 % of the total load) as well as students and doctoral candidates (> 25 % of the total load) will be involved in the project implementation. The project will be implemented from 1 May 2021 and has a duration of 31 months (30 months from the conclusion of the agreement). The implementation of the project activities will be started before signing the agreement on the implementation of the project. The total eligible funding of the project is EUR 540540.54, from which ERDF funding is EUR 444810.81.Key words: Extracellular vesicles, prostate cancer, microfluid, liquid biopsy, optical biosensors. (English)
15 July 2021
0 references
Rātsupītes iela 1 k-1, Rīga, LV-1067
0 references
Ķengaraga iela 8, Rīga, LV-1063
0 references
Identifiers
1.1.1.1/20/A/045
0 references